Accelerating early phase development in the UK and Germany
Recent changes in the regulatory environment post-pandemic and the introduction of EU-CTR 536/2014 are making the UK and Germany more attractive to biotech drug developers. In this video, Parexel experts provide an update on recent early-phase regulatory timelines in the UK and Germany, resulting in trial efficiencies and accelerated approvals for biopharmaceutical companies.
Also, our thought leaders answer your questions about recent changes with the MHRA and EU-CTR process, approval timelines, and the government’s efforts to make these key regions more attractive for conducting clinical trials.
Parexel Biotech can connect every step of development with you. Our Early Phase services combine clinical pharmacology and regulatory expertise to help you move swiftly and efficiently to the proof of concept milestone. Learn more about our clinical units and integrated Early Phase expertise.
Related Insights
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Blog
Best practices for maximizing early-phase trial efficiency to accelerate regulatory timelines
Apr 4, 2024
CTB Blog
EMA’s new pre-submission interactions model pilot: A fundamental shift toward submission readiness and predictable reviews
Sep 30, 2026
Blog
The future of patient recruitment: Building a more connected ecosystem
Sep 9, 2026
Case Study
Speed meets strategy: Delivering a critical FDA 1572 package in just seven days
Sep 9, 2026
Blog
Actioning the commitment letter: The PDUFA VIII changes that matter most to sponsors
Aug 25, 2026
Blog
Data without borders: Assessing China-only evidence for EMA approval – insights from ex-EMA and seasoned subject matter experts
Aug 19, 2026
Blog
The Next Frontier of ADC Development: Navigating an Evolving Regulatory Landscape
Aug 12, 2026
Webinar
From APAC to global: Designing data that travels
Jul 16, 2026
Blog
Regulatory submissions as a source of insight: How AI can amplify the value of our work
Jul 15, 2026
Case Study
Overcoming patient concerns and accelerating enrollment in a hard-to-recruit autoimmune study
Jul 6, 2026
Case Study
Overcoming patient concerns and accelerating enrollment in a hard-to-recruit autoimmune study
Jul 6, 2026
Related Insights
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Blog
Best practices for maximizing early-phase trial efficiency to accelerate regulatory timelines
Apr 4, 2024
CTB Blog
EMA’s new pre-submission interactions model pilot: A fundamental shift toward submission readiness and predictable reviews
Sep 30, 2026
Blog
The future of patient recruitment: Building a more connected ecosystem
Sep 9, 2026
Case Study
Speed meets strategy: Delivering a critical FDA 1572 package in just seven days
Sep 9, 2026
Blog
Actioning the commitment letter: The PDUFA VIII changes that matter most to sponsors
Aug 25, 2026
Blog
Data without borders: Assessing China-only evidence for EMA approval – insights from ex-EMA and seasoned subject matter experts
Aug 19, 2026
Blog
The Next Frontier of ADC Development: Navigating an Evolving Regulatory Landscape
Aug 12, 2026
Webinar
From APAC to global: Designing data that travels
Jul 16, 2026
Blog
Regulatory submissions as a source of insight: How AI can amplify the value of our work
Jul 15, 2026
Case Study
Overcoming patient concerns and accelerating enrollment in a hard-to-recruit autoimmune study
Jul 6, 2026
Case Study
Overcoming patient concerns and accelerating enrollment in a hard-to-recruit autoimmune study
Jul 6, 2026